Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Case Western Reserve Univeristy, School of Medicine, Cleveland, Ohio.
Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Transplant Cell Ther. 2024 Jul;30(7):698.e1-698.e10. doi: 10.1016/j.jtct.2024.01.053. Epub 2024 Jan 19.
Obesity is a common health problem in patients with multiple myeloma (MM) that has been linked to poor clinical outcomes and quality of life (QoL). We conducted a secondary analysis of the BMT CTN 0702, a randomized, controlled trial comparing outcomes of 3 treatment interventions after a single hematopoietic cell transplantation (HCT) (n = 758), to investigate the impact of visceral obesity, as measured by waist-to-hip ratio (WHR), on clinical outcomes and QoL in MM patients. A total of 549 MM patients, median age 55.5 years, were enrolled in the study. The majority of patients received triple-drug antimyeloma initial therapy before enrollment, and 29% had high-risk disease according to cytogenetic assessment. The median duration of follow-up was 6 years. There was no significant association between WHR and progression-free survival (PFS) or overall survival (OS) in MM patients undergoing HCT. Similarly, body mass index (BMI) did not significantly predict PFS or OS. Furthermore, there was no significant correlation between WHR and QoL measures. This study suggests that visceral obesity, as measured by WHR, might not have a significant impact on clinical outcomes in MM patients undergoing HCT. These findings add to the existing literature on the topic and provide valuable information for healthcare professionals and MM patients. Further studies are needed to confirm these results and to investigate other potential factors that may affect clinical outcomes and QoL in this patient population using modern imaging technologies to assess visceral obesity.
肥胖症是多发性骨髓瘤（MM）患者常见的健康问题，与不良临床结局和生活质量（QoL）有关。我们对 BMT CTN 0702 进行了二次分析，该试验是一项随机对照试验，比较了单次造血细胞移植（HCT）后 3 种治疗干预的结局（n = 758），旨在研究内脏肥胖（通过腰臀比（WHR）测量）对 MM 患者临床结局和 QoL 的影响。共有 549 名 MM 患者入组，中位年龄为 55.5 岁。大多数患者在入组前接受了三药抗骨髓瘤初始治疗，根据细胞遗传学评估，29%的患者患有高危疾病。中位随访时间为 6 年。对于接受 HCT 的 MM 患者，WHR 与无进展生存期（PFS）或总生存期（OS）之间没有显著相关性。同样，体重指数（BMI）也不能显著预测 PFS 或 OS。此外，WHR 与 QoL 指标之间也没有显著相关性。这项研究表明，WHR 测量的内脏肥胖可能对接受 HCT 的 MM 患者的临床结局没有显著影响。这些发现增加了关于这一主题的现有文献，并为医疗保健专业人员和 MM 患者提供了有价值的信息。需要进一步的研究来证实这些结果，并使用现代成像技术评估内脏肥胖，以研究其他可能影响这一患者群体临床结局和 QoL 的潜在因素。
